Dr. Andrew Kirker is a clinical assistant professor with the University of British Columbia’s Ophthalmology Department. He attended medical school at the University of British Columbia before completing a residency in ophthalmology at Dalhousie University in Halifax, Nova Scotia. He subsequently undertook surgical retinal fellowship training at the University of British Columbia. Following his training in Vancouver, he completed additional vitreo-retinal training in Calgary before traveling to Philadelphia where he spent time at the Wills’ Eye Institute in the Ocular Oncology service with Drs. Jerry and Carol Sheilds. His last fellowship was in medical retina, Uveitis and Ocular Oncology at the University of Sydney, Australia under the direction of Professor Peter McCluskey.
Dr. Kirker has expertise and performs research in the medical and surgical management of vitreo-retinal surgical diseases, medical retina, and Ocular Oncology.
Crichton AC. Ashenhurst M. Kirker A.W. Gold Implant treatment for discomfort induced by a filtering bleb. Ophthalmic Surgery & Lasers. Sept. 2001, 32(5) 425-7
Crichton AC. Kirker A.W. Intraocular Pressure and medication control after clear corneal phacoemulsification and Acrysof posterior chamber intraocular lens implantation in patients with filtering blebs. Journal of Glaucoma, Feb. 2001 10(1), 38-46
Crichton AC, Oryschak AF, McWhae JA, Kirker AW, Chacon-Andrade H. Postmortem microscopic evaluation and clinical correlation of a pseudophakic eye with pseudoexfoliation and loss of zonular support. J Cataract Refract Surg. 2007 Jan;33(1):162-5.
Kirker AW, Kherani A, Samad A. Intravitreal Bevacizumab for the Treatment of Choriodal Neovascularization Secondary to Pathologic Myopia. Canadian Ophthalmology Society Annual Meeting, e-Poster Presentation, June 2007
Kirker AW, Rafuse PR, Nicolela M, O’Brien D, Morrison D. A comparison of intra-operative intracameral 2% phenylephrine and 0.2% tropicamide with pre-operative topical 2.5 % phenylephrine and 1 % tropicamide for pupillary dilation during cataract surgery on patients with and without Pseudoexfoliation syndrome. Research Day Presentation, Dalhousie University, 2008.
Maberley D, Ma P, Merkur A, Albiani D, Kirker A, Guerami A, Diep T Baker C. A 24 month randomized, double masked, controlled, multi-centre, phase 2b study assessing the safety and efficacy of verteporfin (Visudyne) photodynamic therapy administered in conjunction with ranibizumab (Lucentis) versus ranibizumab monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. In progress.
Clinical Trial Participation
QLT Inc., Protocol Number: BPD OCR 022 (RADICAL) , A Multicenter, Randomized, Single-masked Study Comparing Reduced – fluence-Visudyne ® -Lucentis ® Combination Therapies and Lucentis Monotherapy in Subjects with CNV Secondary to AMD
Regeneron Pharmaceuticals, Inc. Protocol Number:VGFT-OD-0605.01 (VIEW 1) , A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration
Regeneron Pharmaceuticals, Inc. Protocol Number:VGFT-OD-0819 (CRVO) A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
GlaxoSmithKline Identifier: MD7110852 (GSK) , A phase 2b dose-ranging study of pazopanib eye drops for the treatment of neovascular age-related macular degeneration (AMD)